Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 16, 2014. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 7, 2014.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 366,600 Ordinary Shares on May 16, 2014.
- Price Range: Highest price paid was 1,643.50 pence; lowest price paid was 1,631.50 pence.
- Treasury Holdings (Settled): 491,133,712 shares (9.18% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,866,812 shares (10.12% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,859,343,759 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 366,600 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.12% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 9.18% to 10.12% range.
- Confirm the total issued share capital denominator (4,859,343,759 shares) for calculating individual shareholder notification thresholds.
- Check subsequent filings to determine if the unsettled shares mentioned were fully settled.